Home › Malattie autoimmuni › Pennsylvania
Studi clinici su Malattie autoimmuni nello stato di Pennsylvania
21 studi su Malattie autoimmuni cercano partecipanti presso sedi nello stato di Pennsylvania.
Città nello stato di Pennsylvania
Testo ufficiale dello studio (inglese)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06722235A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
In reclutamentoFase 2
Età da 16 a 70 · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07328581RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients, Philadelphia
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients, Pittsburgh
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients, Pittsburgh
In reclutamentoFase 2/3
Età da 6 a 75 · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07103746A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1/2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT06121297Abatacept for the Treatment of Giant Cell Arteritis
- University of Pennsylvania, Philadelphia
In reclutamentoFase 3
Età 50 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT04474847A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- The Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 3
Età 12 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06056297KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Thomas Jefferson University Hospital, Philadelphia
In reclutamentoFase 2/3
Età da 18 a 75 · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- e altri 3
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Pennsylvania, Philadelphia
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT04422912A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
In reclutamentoFase 1
Età da 12 a 70 · Tutti i sessi · Aggiornato il 22 mag 2026 · NCT06308978Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting
- Magee-Womens Hospital, Pittsburgh
In reclutamento
Tutte le età · Uomini · Aggiornato il 22 apr 2026 · NCT04452305Testicular Tissue Cryopreservation for Fertility Preservation
- Magee-Womens Hospital, Pittsburgh
In reclutamento
Tutte le età · Uomini · Aggiornato il 22 apr 2026 · NCT02972801Ovarian Tissue Cryopreservation for Fertility Preservation
- Magee-Womens Hospital, Pittsburgh
In reclutamentoStudio osservazionale
Fino a 39 anni · Donne · Aggiornato il 4 mar 2026 · NCT05875155A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Temple University Hospital, Philadelphia
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 feb 2026 · NCT06626919Central Vein Sign in Multiple Sclerosis Extension Study
- University of Pennsylvania, Philadelphia
In reclutamento
Età da 18 a 65 · Tutti i sessi · Aggiornato il 20 feb 2026 · NCT07424027Autoimmunity After Checkpoint Blockade
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 gen 2026 · NCT04119713X-linked Moesin Associated Immunodeficiency
- Perelman School of medecine, Philadelphia
In reclutamentoStudio osservazionale
Età da 4 a 80 · Uomini · Aggiornato il 25 apr 2025 · NCT06278337Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.